



FOURTH QUARTER & FULL YEAR 2017 RESULTS

February 28, 2018

SAFE HARBOR

This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements

This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.

FORENOTE

Following the announcements in December 2016 of the divestment of the Acetow and Vinythai businesses and in September 2017 of plans to divest the Polyamide business, these have been reclassified as discontinued operations and as assets held for sale. For comparative purposes, the fourth quarter and the full year 2016 income statement have been restated. The Vinythai transaction was completed end of February 2017 and the Acetow transaction end of May 2017. Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators to provide a more consistent and comparable indication of the Group's financial performance. The underlying performance indicators adjust IFRS figures for the noncash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds, classified as equity under IFRS but treated as debt in the underlying statements, and for other elements that would distort the analysis of the Group's underlying performance.



OVERVIEW

- Delivering our plan Financial highlights
- Priorities and outlook
- Annexes



SOLVAY asking more from chemistry®

STRONG EARNINGS GROWTH AND CASH GENERATION



→ Portfolio upgrade completed

- Acetow, Vinythai and Polyamide
- → Strong volumes
 - Leading to 7.5% EBITDA growth

→ Sustained cash generation


- €871 million
- Including 19% increase on continuing operations

Delivering on our plan




[1] constant scope and FX





SIGNIFICANTLY ENHANCED PORTFOLIO MORE GLOBAL, MORE SPECIALTY



SOLID FULL YEAR PERFORMANCE

EBITDA +7.5% (9.7% organic^[1])

- Volume/mix impact of 16%
- Fixed costs effect -6.5% linked to business growth
- EBITDA margin sustained at 22%
- Positive contribution from lower financial charges and reduced tax rate

Underlying EPS^[2] up 26%

Free cash flow **€871m (+19%)**

- Resulting from EBITDA growth and capex discipline
- Underlying net debt reduced to €5.3 billion
- Leverage $2.6x \rightarrow 2.2x$

Cash conversion up 8pp to 68%



[1] constant scope and FX[2] from continuing operations



EXCEEDING MID-TERM TARGETS CREATING MORE VALUE





[1] Underlying EBITDA at constant scope & forex




OVERVIEW

- Executing our plan
- Financial highlights
- Priorities and outlook
- Annexes



SOLVAY asking more from chemistry®

RESILIENT MULTI-SPECIALTY PORTFOLIO VOLUME-DRIVEN GROWTH ACROSS ALL SEGMENTS






Corporate & Business Services included in \in 616 m EBITDA and is excluded from the pie chart as the contribution is negative



HIGHER SALES DRIVEN BY VOLUME & MIX






RECORD EBITDA MARGIN SUSTAINED DRIVEN BY VOLUME GROWTH

Underlying EBITDA

in € million



UNDERLYING NET INCOME REFLECTS SIGNIFICANT INCREASE IN OPERATING PROFIT

Underlying P&L

13


in € m	FY 2017	FY 2016	% уоу
Net sales	10,125	9,569	+6%
EBITDA	2,230	2,075	+7%
EBITDA margin	22%	22%	-
Depreciation & amortization	(704)	(672)	-5%
EBIT	1,527	1,403	+9%
EBIT margin	15%	15%	-
Net financial charges	(394)	(464)	+15%
Income taxes	(299)	(272)	-10%
Tax rate (ytd)	28%	30%	-Зрр
Discontinued operations	159	240	-34%
Non-controlling interests (-)	(54)	(61)	+11%
Profit, Solvay share	939	846	+11%

Underlying profit (Solvay share) up 11%

- Higher EBIT growth versus prior year
- Lower underlying tax rate due to change in geographical mix



IMPROVEMENT IN CASH CONVERSION DRIVEN BY LOWER CAPEX AND HIGHER EBITDA



Profit growth Improved cash conversion

Free cash flow Sustainable improvement






FOCUS ON CASH MAINTAINED €1.2 BILLION REDUCTION IN NET DEBT

Underlying net debt^[1] evolution

in € million



Free cash flow of €871 million


- ↗ Profit growth
- A Capex €716m, 15% lower versus last year
- Working capital discipline maintained

M&A inflow

Net proceeds related to recent divestments (Vinythai, Acetow and other smaller operations)



EFFICIENT CAPITAL STRUCTURE DELEVERAGING CONTINUES



OVERVIEW

- Executing our plan
- Financial highlights
- **Priorities and outlook**
- Annexes



SOLVAY asking more from chemistry®



OUR PRIORITIES DELIVER MID-TERM OBJECTIVES & PREPARE THE FUTURE

Organic volume growth

Earnings and cashflow growth

Optimize our organization

Sustainable value





OUTLOOK FULL YEAR 2018



Underlying EBITDA to grow 5% to 7% organically^[1]

Free cash flow^[2] to exceed 2017 level of €782 million

19 Q4 & FY 2017 Results February 28, 2018

At constant scope and relative to average 2017 forex levels
Free cash flow from continuing operations







Kimberly Stewart +32 2 264 3694 kimberly.stewart@solvay.com



Jodi Allen +1 609 860 4608 jodi.allen@solvay.com



Geoffroy Raskin +32 2 264 1540 geoffroy.raskin@solvay.com



Bisser Alexandrov +32 2 264 3687 bisser.alexandrov@solvay.com



May 3,	May 8,	May 23,	July 31,	November 8,
2018	2018	2018	2018	2018
Q1 2018 results	Annual general meeting	Final dividend payment	Q2 & H1 2018 results	Q3 2018 results






ANNEXES

- Additional FY 2017 financial data
- Q4 2017 financial data
- General information
- Other financial considerations for 2018




asking more from chemistry®

ADVANCED MATERIALS FY 2017



asking more from chemistry®

ADVANCED FORMULATIONS FY 2017



Novecare sales up +16%

- Recovery in North American shale oil & gas activity
- Gradual improvement in the product mix throughout the year
- Moderate demand growth in agro, coatings and industrial applications

Technology Solutions sales up +1%

- Slightly higher but tampered by scope effects following a small divestment
- Mining volumes rose only mildly due to production outages at some customers' copper mines,
- Strong demand for phosphine specialties


Aroma Performance sales up +5%

- Higher sales as the new vanillin plant in China has been ramping up
- Competitive price pressure persist in Asia



23 Q4 & FY 2017 Results February 28, 2018

PERFORMANCE CHEMICALS FY 2017



Soda Ash & Derivatives sales up +4%

- Higher soda ash volumes bound to the seaborne market
- Albeit slightly lower prices
- Bicarbonate sales were stronger, supported by the ramp-up of the new plant in Thailand

Peroxides sales up +11%

- Contribution from the HPPO plant in Saudi Arabia
- The new Chinese plant ramp-up offset lower sales in the bulk and specialties markets

Coatis sales up +18%

- Price increase and modest volume growth lent support
- Signs of recovery in the domestic Latin American market

Functional Polymers sales down -4%


- Activity benefitted from signs of recovery on the domestic Latin American market
- Negative scope effect following a small divestment



24 Q4 & FY 2017 Results February 28, 2018

CORPORATE & BUSINESS SERVICES FY 2017

FRITDA (in E million)



LDIIDA (In€million)			
Key figures		Underlying	
(in € million)	FY 2017	FY 2016	% уоу
Net sales	23	7	n.m.
Energy Services	-	4	n.m.
Other Corporate & Business Services	23	3	n.m.
EBITDA	(244)	(237)	-
Energy Services	21	4	n.m.
Other Corporate & Business Services	(264)	(241)	-

Energy Services

- EBITDA of €21 million versus €4 million in 2016 supported by some favorable market opportunities in the third quarter
- Benefitted from renewable energy projects restructuring in 2016


Other Corporate & Business Services

- €(23) million higher than in 2016 due to higher project costs through the year.
- Fixed costs inflation offset by operational excellence





DEBT PROFILE BALANCED MATURITIES ALLOWING FLEXIBILITY



Major debt ^[1]	December 31, 2016			December 31, 2017			
	Face value	Average maturity	Average cost	Face value	Average maturity	Average cost	
EUR bonds	2,750	4.3	1.97%	1,632	5.5	2.67%	
EUR perpetual hybrid bonds [2]	2,200	5.1	5.07%	2,200	4.1	5.07%	
USD bonds	2,212 ^[3]	6.5	4.03%	1,634 [4]	5.7	3.88%	
Total major debt	7,162	5.2	3.55%	5,465	5.0	4.00%	
	in € m	in years		in€m	in years		




[1] Major debt only, excluding cost of currency swaps [2] At first call date

[3] USD 2,332 m [4] USD 1,960 m



NET PENSION LIABILITIES^[1] DOWN ON CASH CONTRIBUTION AND SCOPE EFFECT



27 Q4 & FY 2017 Results February 28, 2018 [1] Continuing operations only

[2] Average discount rate on post employment benefit related liabilities applicable to high quality corporate bonds in EUR, GBP and USD zones



ANNEXES

Additional FY 2017 financial data

Q4 2017 financial data


General information

Other financial considerations for 2018



SOLVAY asking more from chemistry®


HIGHER SALES DRIVEN BY VOLUME & MIX








RECORD EBITDA MARGIN SUSTAINED DRIVEN BY VOLUME




RESILIENT MULTI-SPECIALTY PORTFOLIO VOLUME-DRIVEN GROWTH ACROSS EACH OPERATING SEGMENT



Corporate & Business Services included in ${\in}\,616$ m EBITDA and is excluded from the pie chart as the contribution is negative




ADVANCED MATERIALS Q4 2017





ADVANCED FORMULATIONS Q4 2017



Novecare sales up +10%

- Stronger volumes thanks to higher North American shale oil & gas activity
- Supportive coatings and industrial applications volumes albeit at a lower level

Technology Solutions sales up +3%


- Recovery in demand from copper and aluminum mining (highest level since 2015)
- Specialty phosphines supported by electronics applications

Aroma Performance sales down -7%

- Stable volumes on high-end vanillin ingredients
- But decrease on lower-grade performance solutions




PERFORMANCE CHEMICALS Q4 2017





CORPORATE & BUSINESS SERVICES Q4 2017 STABLE CONDITIONS

FRITDA (in E million)



LDIIDA (In € million)			
Key figures		Underlying	
(in € million)	Q4 2017	Q4 2016	% уоу
Net sales	7	1	n.m.
Energy Services	-	-	n.m.
Other Corporate & Business Services	7	1	n.m.
EBITDA	(74)	(72)	-
Energy Services	(1)	4	n.m.
Other Corporate & Business Services	(73)	(77)	-

Energy Services

 Negative contribution of €(1) million due to poor business conditions on the cogeneration activity

Other Corporate & Business Services

- €4 million improvement versus 2016
- Fixed costs inflation offset by operational excellence
- Expenses were back-end loaded due to phasing as in previous years



UNDERLYING NET INCOME REFLECTING HIGHER OPERATING PROFIT

Underlying P&L

in € m	Q4 2017	Q4 2016	% уоу
Net sales	2,480	2,431	+2%
EBITDA	494	480	+3%
EBITDA margin	20%	20%	-
Depreciation & amortization	(187)	(184)	-2%
EBIT	307	296	+4%
EBIT margin	12%	12%	-
Net financial charges	(90)	(109)	+17%
Income taxes	(60)	(50)	-20%
Tax rate (ytd)	28%	30%	-Зрр
Discontinued operations	2	66	n.m.
Non-controlling interests (-)	(14)	(21)	+34%
Profit, Solvay share	145	183	-21%


Underlying profit (Solvay share) down 21%

- ↗ Higher EBIT growth versus prior year
- Lower underlying tax rate due to change in geographical mix



FOCUS ON CASH MAINTAINED **REDUCTION IN NET DEBT**

Underlying net debt^[1] evolution



September 30, 2017

37

Higher Free cash flow at €388m

- ↗ Profit growth
- Lower capex 7
- Working capital discipline maintained

M&A outflow

Related to recent small N acquisitions and price & cost adjustments on ongoing divestments

Q4 & FY 2017 Results [1] Underlying net debt reclassifies hybrid perpetual bonds (considered as equity under IFRS) as debt February 28, 2018



ANNEXES

Additional Q4 & FY 2017 financial data

- Q4 2017 financial data
- **General information**

Other financial considerations for 2017



SOLVAY asking more from chemistry®

WE ARE A WORLD LEADER IN THE CHEMICAL INDUSTRY



STRONG DELIVERY IN 2017

						CONTRIBUTOR	
		ADVANCED MATERIALS		ADVANCED FORMULATIONS		PERFORMANCE CHEMICALS	
49% Underlying EBITDA 2017		Providing solutions for sustainable mobility , lightweighting, C0 ₂ and energy efficiency		sustainable mobility, lightweighting, CO ₂ and energy & formulations for surface in chemistry & liquid behavior, maximizing yield & efficiency & minimizing		Leading positions in chemical intermedia through scale & techno developing application industrial innovation f optimized costs	ates logy, is &
Market positions:		Specialty Polymers	#1	Novecare	#1	Soda Ash & Derivatives	s #1
Global market position in main	markets addressed	Composite Materials	#2	Technology Solutions	#1	Peroxides	#1
(#) Regional market position in ma	in markets addressed	Special Chem #1		Aroma Performance	#1	Coatis	#)
		Silica	#1			Functional Polymers	<i>#1</i>)
Net sales	€10,125 m	€4,370 m		€2,966 m		€2,766 m	
Underlying EBITDA	€2,230 m	€1,202 m		€524 m		€749 m	
EBITDA growth	+7.5%	+8.2%		+8.1%		+4.3%	
EBITDA margin	22%	27%		18%		27%	
CFROI	6.9%	10.3%		6.7%		8.4%	

GROWTH ENGINES





RESILIENT CASH

ANNEXES

- Additional Q4 & FY 2017 financial data
- Q4 2017 financial data
- General information

Other financial considerations for 2018



SOLVAY asking more from chemistry®



FINANCIAL CONSIDERATIONS FOR 2018

Depreciation/Amortization & Capex

- D&A expected at ~€(700)m, in line with 2017
 - Excludes PPA amortization
- PPA amortization of ~€(240)m
 - Includes PPA impacts from Rhodia, Cytec and other smaller acquisitions (e.g. Chemlogics, Ryton)
- Capital expenditure from continuing operations expected at ~€(700)m

P&L and cash flow elements

Underlying net financial charges expected at ~€(350)m, excluding foreign exchange fluctuations impact

- Underlying net cost of borrowings at expected at ~€(150)m
- Coupons from perpetual hybrid bonds expected at ~€(112)m (considered as dividend & equity under IFRS)
 - €(84)m in Q2 and €(27)m in Q4
 - Average cost: 5.07%
- Non cash recurring discounting provisions expected at ~€(80)m
- Net cash financing payments at ~€(250)m
- Net debt sensitivity of ~€140m, and net financial charges of ~€5m

Forex sensitivity

- Immediate impact on conversion exposure
- Deferred transactional impact due to hedging (6-12 month rolling basis)
- Mainly linked to USD. Sensitivity in 2018:
 - ~€120 m underlying EBITDA per (0.10) \$/€
 - ~2/3 conversion & ~1/3% transactional
- Other forex exposures
 - CNY, BRL, JPY, RUB, KRW, THB
- Evolution of main currencies Solvay is exposed to:

/€	USD	GBP	JPY	BRL	RUB	CNY	KRW	THB
2016	1.107	0.819	120	3.86	74.14	7.35	1284	39.04
2017	1.130	0.877	127	3.61	65.94	7.63	1277	38.30
(d)evaluation FC in %	2%	7%	5%	-7%	-11%	4%	-1%	-2%

Scope effects

- Divestments having led to restatements in 2017
 - Polyamide planned to be sold to BASF, expected to be completed in the second half of 2018

Tax rate

 Underlying tax rate (adjusted for PPA and other factors) expected at ~26%



SOLVAY'S ADR PROGRAM

CONVENIENCE OF INVESTING IN AMERICAN DEPOSITARY RECEIPTS (ADRS) THROUGH A SPONSORED LEVEL 1 PROGRAM

ADRs Details

ADR Symbol	SOLVY
Platform	OTC
CUSIP	834437303
DR ISIN	US834437305
Underlying ISIN	BE0003470755
SEDOL	BD87R68
Depositary bank	Citi
ADR ratio	1 ORD : 10 ADR

Benefits of ADRs

- Clear and settle according to US standards
- Convenience of stock quotes and dividend payments in US dollars
- Purchase in the same way as other US stocks via a US broker
- Cost effective means of building an international portfolio

For questions about creating Solvay ADRs, please contact Citi

New York Michael O'Leary michael.oleary@citi.com Tel: +1 212 723 4483 London Mike Woods <u>michael.woods@citi.com</u> Tel: +44 20 7500 2030



43 Q4 & FY 2017 Results February 28, 2018